Addiction Clinics Reported Surge in Kratom Withdrawal
As kratom and 7-OH use grows, more patients are seeking professional help for withdrawal symptoms.
Updated on Sept. 21, 2026 in Substance Abuse
Live Poll
Should government agencies impose stricter regulations on over-the-counter wellness supplements?
Data from August 2026 revealed a sharp increase in patients seeking treatment for kratom and 7-hydroxymitragynine (7-OH) withdrawal. This shift reflects rising product potency and broader use across the United States.
Why it matters
Patients are increasingly using concentrated kratom products to self-manage pain or anxiety, but these substances can lead to significant withdrawal symptoms. This surge is pushing more individuals to seek formal clinical support for dependency.
Intake data from Boulder Care showed a rise in patients using kratom or 7-OH, climbing to 14% of new admissions in August 2026 from 3% in September 2025. This coincides with federal reports of 3,434 annual poison center inquiries, up from 258 over the last decade.
The players
Boulder Care
A digital health platform that provides medication-assisted treatment for substance use disorders.
Recovery Centers of America
A network of residential and outpatient addiction treatment facilities.
Drug Enforcement Administration
The federal law enforcement agency responsible for combating drug trafficking and regulating controlled substances.
The details
Highly concentrated 7-hydroxymitragynine, a chemical component often found in supplements, interacts with the brain's opioid receptors. Clinicians are responding to these withdrawal cases using standard evidence-based protocols for opioid use disorder, such as buprenorphine, naloxone, and methadone.
Timeline
2019-2023: Lifetime kratom use rose from 4 million to 5 million people.
September 2025: Kratom users constituted 3% of new patients at Boulder Care.
July 2026: Kratom users accounted for 8% of new patient intakes at Boulder Care.
August 2026: Kratom users reached 14% of new patient intakes at Boulder Care.
Health Landscape
The emergence of concentrated 7-OH products marks a departure from traditional kratom use as a botanical supplement. The pending DEA action on 7-OH follows the established regulatory review procedures defined by the Controlled Substances Act.
If you or a loved one use products containing kratom or 7-OH and experience withdrawal symptoms, consult a physician about evidence-based treatment options. Discuss the specific products being used, as highly concentrated versions may require specialized care for withdrawal management.
The takeaway
The rise of concentrated kratom products has turned a self-managed habit into a clinical concern requiring medical support. If you are experiencing dependence, discuss your usage and withdrawal symptoms with a healthcare provider to explore safe, medically supervised treatment plans.
Further reading
For more information on managing substance dependencies, visit Substance Abuse.
Live Poll
Should government agencies impose stricter regulations on over-the-counter wellness supplements?
